FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296006450> ?p ?o ?g. }

• W4296006450 endingPage "1140" @default.
• W4296006450 startingPage "1140" @default.
• W4296006450 abstract "Type 2 diabetes (T2D)-associated end-stage kidney disease (ESKD) is a global burden, while the renoprotective effects of metformin remain controversial. In a population-based cohort (2002-2018) including 96,643 patients with T2D observed for 0.7 million person-years, we estimated the risk association of metformin and its dose-relationship with ESKD in a propensity-score overlap-weighting (PS-OW) cohort by eGFR categories. Amongst 96,643, 83,881 (86.8%) had eGFR-G1/G2 (≥60 mL/min/1.73 m2), 8762 (9.1%) had eGFR-G3a (≥45-60 mL/min/1.73 m2), 3051 (3.2%) had eGFR-G3b (≥30-45 mL/min/1.73 m2), and 949 (1.0%) had eGFR-G4 (≥15-30 mL/min/1.73 m2). The respective proportions of metformin users in these eGFR categories were 95.1%, 81.9%, 53.8%, and 20.8%. In the PS-OW cohort with 88,771 new-metformin and 7872 other oral glucose-lowering-drugs (OGLDs) users, the respective incidence rates of ESKD were 2.8 versus 22.4/1000 person-years. Metformin use associated with reduced risk of ESKD (hazard ratio (HR) = 0.43 [95% CI: 0.35-0.52] in eGFR-G1/G2, 0.64 [0.52-0.79] in eGFR-G3a, 0.67 [0.56-0.80] in eGFR-G3b, and 0.63 [0.48-0.83] in eGFR-G4). Metformin use was associated with reduced or neutral risk of major adverse cardiovascular events (MACE) (7.2 versus 16.0/1000 person-years) and all-cause mortality (14.6 versus 65.1/1000 person-years). Time-weighted mean daily metformin dose was 1000 mg in eGFR-G1/G2, 850 mg in eGFR-G3a, 650 mg in eGFR-G3b, and 500 mg in eGFR-G4. In a subcohort of 14,766 patients observed for 0.1 million person-years, the respective incidence rates of lactic acidosis and HR in metformin users and non-users were 42.5 versus 226.4 events/100,000 person-years (p = 0.03) for eGFR-G1/G2 (HR = 0.57, 0.25-1.30) and 54.5 versus 300.6 events/100,000 person-years (p = 0.01) for eGFR-G3/G4 (HR = 0.49, 0.19-1.30). These real-world data underscore the major benefits and low risk of lactic acidosis with metformin use down to an eGFR of 30 mL/min/1.73 m2 and possibly even 15 mL/min/1.73 m2, while reinforcing the importance of dose adjustment and frequent monitoring of eGFR." @default.
• W4296006450 created "2022-09-17" @default.
• W4296006450 creator A5017135264 @default.
• W4296006450 creator A5020273125 @default.
• W4296006450 creator A5027757155 @default.
• W4296006450 creator A5034861138 @default.
• W4296006450 creator A5040544030 @default.
• W4296006450 creator A5064838541 @default.
• W4296006450 creator A5074058456 @default.
• W4296006450 creator A5077397829 @default.
• W4296006450 creator A5081052339 @default.
• W4296006450 creator A5091832416 @default.
• W4296006450 date "2022-09-13" @default.
• W4296006450 modified "2023-10-07" @default.
• W4296006450 title "Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1–4" @default.
• W4296006450 cites W1521352086 @default.
• W4296006450 cites W1916095470 @default.
• W4296006450 cites W2036867067 @default.
• W4296006450 cites W2051375321 @default.
• W4296006450 cites W206360234 @default.
• W4296006450 cites W2096250721 @default.
• W4296006450 cites W2112662675 @default.
• W4296006450 cites W2155965977 @default.
• W4296006450 cites W2171294019 @default.
• W4296006450 cites W2414638666 @default.
• W4296006450 cites W2606824216 @default.
• W4296006450 cites W2607031541 @default.
• W4296006450 cites W2742200852 @default.
• W4296006450 cites W2743010525 @default.
• W4296006450 cites W2782341309 @default.
• W4296006450 cites W2806465873 @default.
• W4296006450 cites W2890296042 @default.
• W4296006450 cites W2914902752 @default.
• W4296006450 cites W2922854419 @default.
• W4296006450 cites W2962851941 @default.
• W4296006450 cites W2964576357 @default.
• W4296006450 cites W2974039187 @default.
• W4296006450 cites W2985331915 @default.
• W4296006450 cites W2998114686 @default.
• W4296006450 cites W2999253935 @default.
• W4296006450 cites W3009389584 @default.
• W4296006450 cites W3011104356 @default.
• W4296006450 cites W3019600263 @default.
• W4296006450 cites W3023814660 @default.
• W4296006450 cites W3042176300 @default.
• W4296006450 cites W3043523396 @default.
• W4296006450 cites W3088173406 @default.
• W4296006450 cites W3092470915 @default.
• W4296006450 cites W3092536569 @default.
• W4296006450 cites W3093725239 @default.
• W4296006450 cites W3095022414 @default.
• W4296006450 cites W3099453602 @default.
• W4296006450 cites W3134769649 @default.
• W4296006450 cites W3153727945 @default.
• W4296006450 cites W4200028200 @default.
• W4296006450 cites W4210495025 @default.
• W4296006450 cites W4224253280 @default.
• W4296006450 cites W4283362961 @default.
• W4296006450 doi "https://doi.org/10.3390/ph15091140" @default.
• W4296006450 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36145361" @default.
• W4296006450 hasPublicationYear "2022" @default.
• W4296006450 type Work @default.
• W4296006450 citedByCount "6" @default.
• W4296006450 countsByYear W42960064502022 @default.
• W4296006450 countsByYear W42960064502023 @default.
• W4296006450 crossrefType "journal-article" @default.
• W4296006450 hasAuthorship W4296006450A5017135264 @default.
• W4296006450 hasAuthorship W4296006450A5020273125 @default.
• W4296006450 hasAuthorship W4296006450A5027757155 @default.
• W4296006450 hasAuthorship W4296006450A5034861138 @default.
• W4296006450 hasAuthorship W4296006450A5040544030 @default.
• W4296006450 hasAuthorship W4296006450A5064838541 @default.
• W4296006450 hasAuthorship W4296006450A5074058456 @default.
• W4296006450 hasAuthorship W4296006450A5077397829 @default.
• W4296006450 hasAuthorship W4296006450A5081052339 @default.
• W4296006450 hasAuthorship W4296006450A5091832416 @default.
• W4296006450 hasBestOaLocation W42960064501 @default.
• W4296006450 hasConcept C126322002 @default.
• W4296006450 hasConcept C134018914 @default.
• W4296006450 hasConcept C143998085 @default.
• W4296006450 hasConcept C159641895 @default.
• W4296006450 hasConcept C207103383 @default.
• W4296006450 hasConcept C2777180221 @default.
• W4296006450 hasConcept C2778653478 @default.
• W4296006450 hasConcept C2780323712 @default.
• W4296006450 hasConcept C2908647359 @default.
• W4296006450 hasConcept C44249647 @default.
• W4296006450 hasConcept C50382708 @default.
• W4296006450 hasConcept C555293320 @default.
• W4296006450 hasConcept C71924100 @default.
• W4296006450 hasConcept C72563966 @default.
• W4296006450 hasConcept C98274493 @default.
• W4296006450 hasConcept C99454951 @default.
• W4296006450 hasConceptScore W4296006450C126322002 @default.
• W4296006450 hasConceptScore W4296006450C134018914 @default.
• W4296006450 hasConceptScore W4296006450C143998085 @default.
• W4296006450 hasConceptScore W4296006450C159641895 @default.
• W4296006450 hasConceptScore W4296006450C207103383 @default.

• next